Fluorescent signal lymph node mapping using indocyanine green in early breast cancer patients (Botkin Hospital experience)

Modern diagnostic methods with more accurate staging of the tumor process and effective high-tech treatment of breast cancer are very relevant, since this disease ranks first in the structure of cancer morbidity and mortality among women. Mapping of the signal lymph node is an alternative to axillary lymphatic dissection in patients with clinically intact regional lymph nodes (cN0). This allows patients to avoid such formidable, often and disabling complications of lymphatic dissection as prolonged postoperative lymphorrhea and lymphatic swelling of the upper extremity (lymphostasis). Radioisotope is the standard method of performing lymph node mapping, but recent years there have been more and more scientific studies and publications on the effectiveness of the non-toxic and non-radioisotope method in oncosurgery – fluorescent lymphography with indocyanine green.
This article analyzes the experience and results of performing a mapping signal lymph node by a fluorescent method with indocyanine green at an early staged breast cancer in the Botkin Hospital, Moscow.

1. International Agency for Research on Cancer (IARC). Available at: https://www.iarc.who.int/.

2. Breast Cancer. Clinical Recommendations. 2021. Available at: https://cr.minzdrav.gov.ru/schema/379_4. (In Russ.).

3. Fisher B., Montague E., Redmond C. et al. Findings from NSABP protocol No. B-04 – comparison of radical mastectomy with alternative treatments for primary breast cancer. Cancer 1980;46(1):1–13.

4. Gould E.A., Winship T., Philbin P.H., Kerr H.H. Observations on a “sentinel node” in cancer of the parotid. Cancer 1960;13:77–8.

5. Breast Cancer. NCCN Guidelines. Version 4.2020.

6. Pellini F., Bertoldi L., Deguidi G. The use of indocyanine green as the only tracer for the identification of the sentinel lymph node in breast cancer: Safety and feasibility. Gland Surg 2022;11(7): 1139–47. DOI: 10.21037/gs-21-609

7. Valente S.A., Al-Hilli Z., Radford D.M. Near infrared fluorescent lymph node mapping with indocyanine green in breast cancer patients: A prospective trial. J Am Coll Surg 2019;228:672–8. DOI: 10.1016/j.jamcollsurg.2018.12.001

8. Starkova M.V., Zikiryakhodzhaev A.D., Grushina T.I. Diagnostics of sentinel lymph node using radioisotope colloid. Mistakes and opportunities. Vestnik Soveta molodykh uchenykh i specialistov Chelyabinskoy oblasti = Bulletin of the Council of Young Scientists and Specialists of the Chelyabinsk Region 2018;2(1–20):92, 93. (In Russ.).

9. Senkus E., Kyriakides S., Penault-Llorca F. et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):7–23. DOI: 10.1093/annonc/mdt284

10. Jinno H., Inokuchi M., Ito T. et al. The Japanese Breast Cancer Society clinical practice guideline for surgical treatment of breast cancer, 2015 edition. Breast Cancer 2016;23:367–77. DOI: 10.1007/s12282-016-0671-x

11. Sugie T., Ikeda T., Kawaguchi A. et al. Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: A meta-analysis. Int J Clin Oncol 2017;22:11–7. DOI: 10.1007/s10147-016-1064-z

12. Gentilini O.D., Botteri E., Sangalli C. et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: The SOUND randomized clinical trial. JAMA Oncol 2023;9(11):1557–64. DOI: 10.1001/jamaoncol.2023.3759

13. Straver M.E., Meijnen P., van Tienhoven G. et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS Trial. Ann Surg Oncol 2010;17(7):1854–61. DOI: 10.1245/s10434-010-0945-z

14. Ngô C., Sharifzadehgan S., Lecurieux-Lafayette C. et al. Indocyanine green for sentinel lymph node detection in early breast cancer: Prospective evaluation of detection rate and toxicity – The FLUOBREAST trial. Breast 2020;26(12):2357–63. DOI: 10.1111/tbj.14100